ANGELALIGN (06699) Asserts European Court's Preliminary Ruling on Specific Software Feature Has Minimal User Impact

Stock News
昨天

ANGELALIGN TECHNOLOGY INC. (06699, hereinafter referred to as "ANGELALIGN") has stated that a provisional injunction issued by the Unified Patent Court of Düsseldorf, Germany, requiring the company to suspend the use of a specific module within its automatic update solution feature ("Live Now"), will have minimal impact on doctors and patients using ANGELALIGN's clear aligner products. This provisional injunction applies only to certain European countries and excludes Spain, Switzerland, the United Kingdom, and Ireland. The company will launch a newly upgraded iPlan function for affected European users, which not only offers equivalent reliability but also provides greater flexibility. ANGELALIGN stated that the Live Now feature within its orthodontic treatment design software, iOrtho, does not infringe upon any valid patents held by Align Technology. The company has submitted a patent opposition to the European Patent Office (EPO), arguing that the invention described in the patent lacks both novelty and inventive step compared to prior art, and is seeking a permanent invalidation of the patent. The ruling by the Düsseldorf Unified Patent Court is only a first-instance decision and is not final; ANGELALIGN expressed confidence in having it overturned. Dr. Arno Riße, the attorney from ANGELALIGN's German representative law firm Arnold Ruess, stated: "ANGELALIGN respects and will comply with the ruling from the Düsseldorf Unified Patent Court. However, we will actively present evidence to demonstrate that the injunction against the specific module of the Live Now function is unreasonable. ANGELALIGN places great importance on intellectual property rights and consistently ensures it does not infringe upon any valid patent rights." For many years, ANGELALIGN has focused on developing innovative solutions in the clear aligner sector. The company possesses numerous cutting-edge solutions and products, including the award-winning angelButton, angelHook, the A6 mandibular advancement solution (celebrating its tenth anniversary), the angel KiD solution for children, and the IRS intelligent root-bone system. ANGELALIGN is committed to fostering a fair and healthy competitive market that benefits both doctors and patients. The company has consistently received high satisfaction ratings from doctors. Leveraging its flexible manufacturing system, ANGELALIGN translates complex clinical concepts into practical solutions, earning widespread recognition. Through its continuous innovation, ANGELALIGN has achieved robust global growth and intends to maintain this positive trajectory.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10